Technology and healthcare-focused investment firm Polaris Partners has promoted Kevin Bitterman to partner after a decade at the firm.
Bitterman, who deals with healthcare investing for the firm, was co-founder of Sirtris Pharmaceuticals and Genocea Biosciences, which were sold to GlaxoSmithKline and listed on the Nasdaq stock exchange respectively.
Polaris managing partner Amir Nashat said, “For nearly a decade, Kevin has delivered incredible value to our partnership and our companies.
“His passion for science, entrepreneurial spirit, and pragmatic approach to company building has proven to be a tremendous asset for our portfolio.
“We are thrilled to recognize his commitment with this promotion and we look forward to his continued contributions now as a partner in the firm.”
Polaris was launched in 1996 and has more than $3.5bn of capital under management.
One of Polaris’ most recent investments was in genome editing specialist Editas Medicine as part of a $43m Series A round.
Flagship Ventures and Third Rock Ventures also took part in the financing for Editas, which attempts to use genome editing technology to treat the underlying cause of a broad range of diseases at the genetic level.
Copyright © 2014 AltAssets